NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/01/2023
Back to search
Official data from USPTO
PROTEOVANT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PROTEOVANT
ST13
US500000090858111Class
5, 42, 44
Filing
90858111
Registration
7123854
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
08/01/2023
Trademark type
Word
Nice classes
5, 42, 44
Filing date
07/30/2021
Registration date
08/01/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/01/2023
Last transaction
08/01/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Basel, CH
Examiner
SINGH, TEJBIR
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Roivant Sciences GmbH
Representatives
Allison Strickland Ricketts FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncologicalallergy and immunologicalneurologicalcardiacdermatologicalendocrinologicalgastroenterologicalhematologicalinfectiousgeneticnephrologicalgynecologicalophthalmologicalorthopedicotorhinolaryngologicalpodiatricpsychiatricpulmonologicalrespiratoryrheumatologicalurological diseases and disorders; biologic preparations for medical and therapeutic purposes comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncologicalallergy and immunologicalneurologicalcardiacdermatologicalendocrinologicalgastroenterologicalhematologicalinfectiousgeneticnephrologicalgynecologicalophthalmologicalorthopedicotorhinolaryngologicalpodiatricpsychiatricpulmonologicalrespiratoryrheumatologicalurological diseases and disorders; pharmaceutical and biological preparations for treatment and prevention of cancer and for the treatment and prevention of auto-immune diseases and disorders and central nervous system and neurological diseases and disorders
Class 42
Pharmaceutical product development for new small molecules aimed at degrading disease-causing cellular proteins for treatment in the field of oncology; scientific and technological servicesmedical researchscientific research and analysis in the field of pharmaceuticals and biomedicine; pharmaceutical and biomedical research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical research and development; providing scientific research information in the field of pharmaceuticals and biomedicine
Class 44
Providing health and medical information; providing information relating to the diagnosticprophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseasesdisorders and conditions
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/16/2023
PUBO
PUBLISHED FOR OPPOSITION
05/16/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/26/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
04/12/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
04/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/17/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/17/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/17/2023
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
02/28/2023
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
02/28/2023
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
02/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/15/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/14/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/29/2022
GNFR
FINAL REFUSAL E-MAILED
11/29/2022
CNFR
FINAL REFUSAL WRITTEN
11/29/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/28/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/27/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/27/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/27/2022
GNRT
NON-FINAL ACTION E-MAILED
04/27/2022
CNRT
NON-FINAL ACTION WRITTEN
04/27/2022
DOCK
ASSIGNED TO EXAMINER
04/27/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
10/05/2021
ALIE
ASSIGNED TO LIE
10/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/27/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/04/2021
NWAP
NEW APPLICATION ENTERED
08/03/2021
Continuous trademark protection
Get notified about every new filing that threatens PROTEOVANT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.